| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2008;39:1033.)
© 2008 American Heart Association, Inc.
Research Letters |
' in Ischemic StrokeFrom the Departments of Hematology (E.Y.L.C., F.W.G.L., M.P.M.M.), and Neurology (D.W.J.D.), Erasmus University Medical Center, Rotterdam; and The Haemostasis and Thrombosis Research Center (S.U.W., H.L.V., R.M.B), Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
Correspondence to Moniek P.M. de Maat, Erasmus University Medical Center, Department of Hematology, Room L431, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. E-mail m.demaat{at}erasmusmc.nl
Background and Purpose— To determine the contribution of fibrinogen
' levels and FGG haplotypes to ischemic stroke.
Methods— Associations between fibrinogen
' levels, fibrinogen
'/total fibrinogen ratio, and FGG haplotypes with the risk of ischemic stroke were determined in 124 cases and 125 controls.
Results— Fibrinogen
'/total fibrinogen ratio was higher in patients than in controls during the acute phase of the stroke and lower in the convalescent phase 3 months after the stroke. FGG haplotype 3 (H3) was associated with a reduced risk of ischemic stroke (odds ratio 0.60; 95% CI, 0.38 to 0.94), but not with the fibrinogen
'/total fibrinogen ratio. In contrast, FGG-H2 was associated with a decreased fibrinogen
'/total fibrinogen ratio, but not with risk of stroke.
Conclusions— Fibrinogen
'/total fibrinogen ratio is associated with ischemic stroke, especially in the acute phase of the disease. In addition, FGG-H3 haplotype appears to be protective against ischemic stroke.
Key Words: FGG haplotypes fibrinogen
'/total fibrinogen ratios ischemic stroke
This article has been cited by other articles:
![]() |
E. Y. L. Cheung, H. L. Vos, M. J. H. A. Kruip, H. M. den Hertog, J. W. Jukema, and M. P. M. de Maat Elevated fibrinogen {gamma}' ratio is associated with cardiovascular diseases and acute phase reaction but not with clinical outcome Blood, November 12, 2009; 114(20): 4603 - 4604. [Full Text] [PDF] |
||||
![]() |
S. Uitte de Willige, K. F. Standeven, H. Philippou, and R. A. S. Ariens The pleiotropic role of the fibrinogen {gamma}' chain in hemostasis Blood, November 5, 2009; 114(19): 3994 - 4001. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Nowak-Gottl, H. Weiler, I. Hernandez, S. Thedieck, T. Seehafer, T. Schulte, and M. Stoll Fibrinogen {alpha} and {gamma} genes and factor VLeiden in children with thromboembolism: results from 2 family-based association studies Blood, August 27, 2009; 114(9): 1947 - 1953. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lancellotti, S. Rutella, V. De Filippis, N. Pozzi, B. Rocca, and R. De Cristofaro Fibrinogen-elongated {gamma} Chain Inhibits Thrombin-induced Platelet Response, Hindering the Interaction with Different Receptors J. Biol. Chem., October 31, 2008; 283(44): 30193 - 30204. [Abstract] [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |